Evidence map›Paper›PMID 22937084›Full record

ArticlePloS one2012

Calpain/SHP-1 interaction by honokiol dampening peritoneal dissemination of gastric cancer in nu/nu mice.

Shing Hwa Liu, Keh Bin Wang, Keng Hsin Lan, Wen Jane Lee, Hung Chuan Pan, Sheng Mao Wu, Yen Chun Peng, Yi Ching Chen, Chin Chang Shen, Hsu Chen Cheng and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
6.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 52 citations in OpenAlex.

  1. Review
  2. Article
  3. Evidence-based complementary and alternative medicine : eCAM · 2022
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Honokiol induces cell cycle arrest and apoptosis in human gastric carcinoma MGC-803 cell line.International journal of clinical and experimental medicine · 2015
    Article
  16. Article
  17. Honokiol as a Radiosensitizing Agent for Colorectal cancers.Current colorectal cancer reports · 2013
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Shing Hwa LiuInstitute of Toxicology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Keh Bin Wang
Keng Hsin Lan
Wen Jane Lee
Hung Chuan Pan
Sheng Mao Wu
Yen Chun Peng
Yi Ching Chen
Chin Chang Shen
Hsu Chen Cheng
Ko Kaung Liao
Meei Ling Sheu
Taichung Veterans General Hospital · TWNational Chung Hsing University · TWNational Taiwan University · TWChung Shan Medical University · TWKuang Tien General Hospital · TWTaipei Veterans General Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHonokiol, a small-molecular weight natural product, has previously been reported to activate apoptosis and inhibit gastric tumorigenesis. Whether honokiol inhibits the angiogenesis and metastasis of gastric cancer cells remains unknown. METHODOLOGY/PRINCIPAL

findingsWe tested the effects of honokiol on angiogenic activity and peritoneal dissemination using in vivo, ex vivo and in vitro assay systems. The signaling responses in human gastric cancer cells, human umbilical vascular endothelial cells (HUVECs), and isolated tumors were detected and analyzed. In a xenograft gastric tumor mouse model, honokiol significantly inhibited the peritoneal dissemination detected by PET/CT technique. Honokiol also effectively attenuated the angiogenesis detected by chick chorioallantoic membrane assay, mouse matrigel plug assay, rat aortic ring endothelial cell sprouting assay, and endothelial cell tube formation assay. Furthermore, honokiol effectively enhanced signal transducer and activator of transcription (STAT-3) dephosphorylation and inhibited STAT-3 DNA binding activity in human gastric cancer cells and HUVECs, which was correlated with the up-regulation of the activity and protein expression of Src homology 2 (SH2)-containing tyrosine phosphatase-1 (SHP-1). Calpain-II inhibitor and siRNA transfection significantly reversed the honokiol-induced SHP-1 activity. The decreased STAT-3 phosphorylation and increased SHP-1 expression were also shown in isolated peritoneal metastatic tumors. Honokiol was also capable of inhibiting VEGF generation, which could be reversed by SHP-1 siRNA transfection. CONCLUSIONS/SIGNIFICANCE: Honokiol increases expression and activity of SPH-1 that further deactivates STAT3 pathway. These findings also suggest that honokiol is a novel and potent inhibitor of angiogenesis and peritoneal dissemination of gastric cancer cells, providing support for the application potential of honokiol in gastric cancer therapy.

Indexed as

Allyl CompoundsAnimalsApoptosisBiphenyl CompoundsCalpainCell Line, TumorCell ProliferationCells, CulturedHumansHuman Umbilical Vein Endothelial CellsLignansMiceNeovascularization, PathologicPhenolsPhosphorylationProtein Tyrosine Phosphatase, Non-Receptor Type 6Allyl CompoundsBiphenyl CompoundsCalpainhonokiolLignansPhenolsProtein Tyrosine Phosphatase, Non-Receptor Type 6RNA, Small InterferingSTAT3 Transcription Factor

Identifiers

PMID22937084
PMCPMC3427156
OpenAlexW1973613494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.